- | Immunomedics
Sisters Network spreads awareness of new TNBC treatment
When Karen Jackson founded Sisters Network INC. in 1994, a national African American breast cancer survivorship organization, she was optimistic to the point of wearing rose-colored glasses about the healthcare industry. She believed that if someone was sick then there would be someone to help.Your Content Goes Here
- | NantKwest
Tackling a “Genius Virus”: Dr Patrick Soon-Shiong
Dr. Patrick Soon-Shiong is a physician, surgeon, researcher, philanthropist, and owner of the LA Times. From 1997–2010, he served as Founder, Chairman and CEO of American Pharmaceutical Partners (APP) and Abraxis BioScience, where he developed the drug Abraxane, which received FDA approval for the treatment of metastatic breast cancer, lung cancer, and advanced pancreatic cancer. In 2008, he sold APP to Fresenius for approximately $4.6 billion. Two years later, he sold Abraxis to Celgene for approximately $3.8 billion.
- | Acepodia
A New Cost Paradigm For CAR Cell Therapies?
Efficacy, safety, and convenience are hard-to-achieve attributes of cancer therapies, despite the best marketing engines in biopharma. Acepodia—a clinical-stage biotech focused on developing novel, targeted, allogeneic-cell based immunotherapies to treat cancers—has the gall to add affordable to the list of product attributes it’s striving for.
- | NantKwest
‘I feel good. I’m alive’: Two years after diagnosis, Harry Reid says he’s cancer free
Harry M. Reid has a message for these incredibly bleak times: Keep fighting. Last summer the former Senate majority leader hid from the obvious fact that pancreatic cancer was on the verge of defeating him. “I wasn’t willing to acknowledge that I was about to get hit by the Grim Reaper,” Reid (D-Nev.) said Thursday in a 45-minute telephone interview.
- | NantKwest
Doctor who treated former Nevada Sen. Harry Reid’s cancer now focusing on coronavirus
The scientist whose unorthodox approach helped former Senate Majority Leader Harry Reid beat pancreatic cancer is turning his attention toward fighting coronavirus. Dr. Patrick Soon-Shiong, who said his company ImmunityBio is working with the Department of Health and Human Services on a coronavirus vaccine, said the same treatment that worked on Reid’s cancer could be used to fight infectious diseases.
- | Rezolute
How an Israeli web service, a bong-like insulin device and a Bay Area deal led this Peninsula biotech to attack a childhood disease
With deep roots in diabetes, this small company is pushing forward with a trial against a rare diosease known as congenital hyperinsulinism.
- | Immuneering Corp.
Woman of the Week Podcast
Dr. Rebecca Kusko, Chief Strategy Officer at Immuneering Corp., has carved out a purposeful, yet unorthodox, path to the C-suite as well as serving as a mentor to women. Trained as a computational biologist, she is using her love for creative problem solving to benefit patients.
- | Ziopharm Oncology
Genetic Manipulation of T-cells Driving Next Generation Immuno-Oncology with Dr. Laurence Cooper Ziopharm
Dr. Laurence Cooper, CEO, Ziopharm Oncology points to earlier work in immunotherapy to explain the advances in cancer treatment that revolve around the genetic engineering of cells to control gene expression and manipulation of the DNA of cells such as T-cells to go after cancer cells. The next generation immunotherapy will allow cells and agents to adapt in real time to overcome resistance and empower T-cells to go after the cancer weak spots.
